No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
APGE250117C40000
- 10.50
- 0.000.00%
15min DelayTrading Aug 13 09:48 ET
0.00High0.00Low
0.00Open10.50Pre Close0 Volume16 Open Interest40.00Strike Price0.00Turnover54.20%IV6.72%PremiumJan 17, 2025Expiry Date7.32Intrinsic Value100Multiplier25DDays to Expiry3.18Extrinsic Value100Contract SizeAmericanOptions Type0.9128Delta0.0233Gamma6.15Leverage Ratio-0.0256Theta0.0244Rho5.61Eff Leverage0.0199Vega
Intraday
- 5D
- Daily
News
Apogee Therapeutics Director Mark McKenna Acquires $990,775 in Stock
Guggenheim Reiterates Buy on Apogee Therapeuticsto Buy
Apogee Therapeutics Advances Clinical Trials for APG333
Express News | Apogee Therapeutics Inc - Interim Data From Phase 1 Trial Expected in 2H 2025
Express News | Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of Apg333, Its Novel Half-Life Extended Tslp Antibody for the Treatment of Respiratory and Broader I&I Conditions
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, Its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions